Last reviewed · How we verify
HAVRIX
At a glance
| Generic name | HAVRIX |
|---|---|
| Also known as | INFANRIX, BOOSTRIX, Havrix™, GSK Biologicals' hepatitis A vaccine, inactivated |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection-site soreness
- Headache
- Fatigue
- Fever >99.5°F (37.5°C)
- Induration, redness, and swelling of injection site
- Malaise
- Nausea
- Anorexia
Serious adverse events
- Injection-site soreness (severe)
Key clinical trials
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (PHASE4)
- Trial of Antibody Responses by Vitamin Supplementation (PHASE1)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) (PHASE3)
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |